Endocrinology practices manage some of the most documentation-intensive chronic disease coding in medicine—from diabetes CGM billing to thyroid ultrasound interpretation. VeriMedix delivers specialized RCM that captures every billable service while keeping you audit-ready.
Endocrinology billing sits at the intersection of chronic disease management, advanced diagnostics, and increasingly complex payer rules around diabetes technology. The specialty relies heavily on evaluation and management (E/M) coding under the 2021 AMA guidelines, where medical decision-making (MDM) complexity—driven by multiple chronic conditions like Type 2 diabetes with complications, hypothyroidism, and adrenal insufficiency—often supports higher-level 99214 and 99215 visits. Coders must map each encounter to the correct ICD-10-CM block: E10–E14 for diabetes, E00–E07 for thyroid disorders, E20–E35 for adrenal/pituitary conditions, and E66 for obesity, ensuring combination codes capture comorbidities such as diabetic chronic kidney disease (E11.65) or diabetic neuropathy (E11.40).
Continuous glucose monitoring (CGM) represents one of the fastest-growing—and most frequently miscoded—revenue streams in endocrinology. CPT 95249 covers ambulatory CGM with patient-provided equipment (physician interpretation only), 95250 covers professional CGM placement, training, and data download, and 95251 covers physician interpretation and reporting for CGM data. Payer coverage policies differ sharply: Medicare covers CGM for beneficiaries on intensive insulin therapy under DMEPOS rules (A9276–A9278 for supplies), while commercial payers may bundle interpretation into the E/M. Insulin pump management codes (95110 is obsolete; use 99213–99215 with ICD-10 Z96.41 or the underlying diabetes code) and therapeutic continuous glucose monitor supply HCPCS codes must align with the correct beneficiary eligibility category. Telehealth delivery of CGM education and virtual check-ins (G2012, G2010) adds another layer of documentation requirements.
Thyroid ultrasound interpretation (76536, professional component with modifier -26 when equipment is owned by a facility), fine needle aspiration biopsy (10005–10012 series for ultrasound-guided procedures), and nuclear medicine thyroid uptake studies (78012, 78013, 78014) require accurate component billing and coordination with radiology or pathology. Bone density (DXA, CPT 77080) is frequently performed in endocrinology offices and is subject to Medicare coverage requirements for osteoporosis diagnosis (M80–M81 ICD-10). Errors in frequency limitations, missing clinical indication diagnoses, and failure to append modifier -26 or -TC correctly are among the top drivers of denied claims. A dedicated endocrinology billing team understands these nuances and ensures that every diagnostic, therapeutic, and management service is coded to its highest specificity and captured on a clean claim.
Below are commonly billed codes our certified coders manage for endocrinology practices. Always confirm payer-specific coverage and current code values.
| Code | Description | Billing note |
|---|---|---|
99214 | Office/outpatient E/M, established patient, moderate complexity (MDM) | Most common endocrinology visit level; requires MDM with multiple chronic conditions or prescription drug management |
99215 | Office/outpatient E/M, established patient, high complexity (MDM) | Appropriate for unstable DM with multiple complications or adrenal crisis follow-up; document data reviewed and risk |
95250 | Ambulatory continuous glucose monitoring, professional; sensor placement, hook-up, calibration, patient training, removal, physician interpretation | Used when practice owns/provides the CGM device; requires 72-hour minimum recording |
95251 | Ambulatory CGM—physician interpretation and report only | Billable separately from 95250; requires signed interpretation; not separately payable with most E/M on same day by Medicare |
95249 | Ambulatory CGM, patient-provided equipment; physician review and interpretation | Patient owns device (e.g., Dexcom G7); only interpretation is billed by physician |
77080 | DXA bone density study, axial skeleton (hips/spine) | Medicare covers every 2 years for eligible beneficiaries; ICD-10 M81.0 or risk-factor codes required |
76536 | Ultrasound, soft tissues of head and neck (thyroid) | Professional component -26 when facility owns equipment; document clinical indication in report |
10005 | FNA biopsy, including ultrasound guidance, first lesion | Replaced 10021/10022; use 10006 for each additional lesion |
78014 | Thyroid imaging; with uptake (single or multiple) | Nuclear medicine; requires facility/camera certification; separate technical and professional components |
Our standard operating procedures for endocrinology revenue cycle management — the step-by-step workflow we follow on every claim:
These are the issues we see most often in endocrinology billing — and exactly how we resolve them:
Medicare distinguishes between therapeutic CGM (covered under DMEPOS if patient uses intensive insulin) and non-therapeutic CGM (not covered). Billing 95250/95251 for a patient who does not qualify for the intensive insulin category results in denial. Fix: Verify insulin regimen at intake, document in chart, append -KX modifier, and route supply codes A9276–A9278 through the DMEPOS MAC, not Part B.
Many payers bundle 95251 into the E/M when both are billed on the same date of service. Fix: Append modifier -25 to the E/M to document that it was a significant, separately identifiable service; add a distinct note section covering the CGM data analysis separate from the encounter note.
Using generic E11.9 (T2DM without complications) when the chart clearly documents neuropathy, retinopathy, or CKD leaves money on the table and risks medical necessity denials for specialist consultations. Fix: Train providers to document specific complications at every encounter; use E11.40–E11.649 combination codes to support higher-acuity MDM and downstream authorization approvals.
Practices that perform ultrasounds in a hospital-owned outpatient department or use facility equipment must bill only the professional component with -26. Billing global code (76536 without -26) in a facility setting results in overpayment and potential recoupment. Fix: Configure the billing system to automatically append -26 when the place of service is 22 (outpatient hospital) or 19 (off-campus outpatient hospital).
Submitting a DXA claim within 24 months of the previous scan without a clinical override triggers an automatic Medicare denial. Fix: Flag DXA orders in the scheduling system with the last scan date; if medically necessary earlier, obtain payer pre-authorization and document the clinical rationale (e.g., new vertebral fracture, initiation of high-risk medication).
Verimedix works inside the systems endocrinology practices already use, including:
Yes, but modifier -25 must be appended to the E/M code to indicate it was a significant and separately identifiable service beyond the pre/post-service work of the CGM interpretation. Document the two services distinctly in the medical record. Some commercial payers still bundle; review each payer's policy and appeal with supporting documentation.
Common supporting codes include M81.0 (age-related osteoporosis without fracture), Z87.310 (personal history of osteoporosis), Z79.52 (long-term use of systemic steroids), E21.0 (primary hyperparathyroidism), and E34.9 (endocrine disorder, unspecified). Medicare requires at least one qualifying condition; document the clinical basis in the order.
There is no standalone CPT code for insulin pump management as of 2024. Bill an appropriate E/M code (99213–99215) based on MDM complexity, using Z96.41 (presence of insulin pump) as a secondary diagnosis alongside the primary diabetes ICD-10 code. Time-based billing is an alternative if total physician time is documented.
Medicare covers intensive behavioral therapy for obesity (G0447, 15 minutes) in the primary care setting, not typically in specialty settings. However, 99401–99404 (preventive counseling) and 97803 (medical nutrition therapy, re-assessment) may apply for commercial payers. Verify each payer's policy; use -GY on Medicare claims for non-covered services so secondary payers process correctly.
CPT 10005 covers ultrasound-guided FNA of the first lesion (includes guidance); 10006 is each additional lesion. Do not additionally bill 76942 (ultrasound guidance for needle placement) as it is bundled into 10005. Pathology (88172 or 88173 for cytopathology) is billed separately by the interpreting pathologist.
Use standard E/M codes (99213–99215) with place of service 02 (telehealth) or 10 (telehealth in patient's home) and modifier -95 for synchronous audiovisual visits. G2012 applies for brief check-in telephone calls (5–10 minutes). Document that the patient consented to telehealth. Payer coverage for telehealth beyond Medicare flexibilities varies—verify commercial payer telehealth policies annually.
Verimedix handles the entire endocrinology revenue cycle — coding, submission, denials, and A/R — so your team can focus on patients.